

Cetrotide® (cetrorelix) – First-time generic

- On October 24, 2022, <u>Akorn launched</u> an <u>AP-rated</u> generic version of EMD Serono's <u>Cetrotide</u> (<u>cetrorelix</u>) subcutaneous injection.
 - The FDA granted Akorn's generic Cetrotide <u>180-days of Competitive Generic Therapy</u>.
- Cetrotide is approved for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian stimulation.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.